First-line treatment of camrelizumab combined with chemotherapy in advanced gastroenteropancreatic neuroendocrine carcinoma: Study protocol for a prospective, multicenter, phase II study

BACKGROUND: Gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) is a group of rare but highly aggressive malignancies. The standard chemotherapy regimens composed of etoposide and cisplatin/carboplatin (EP/EC) are of limited efficacy. This prospective, multicenter, phase II study is conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xiaofen, Ma, Qing, Chang, Chen, Li, Hao, Cao, Dan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524149/
https://www.ncbi.nlm.nih.gov/pubmed/36185252
http://dx.doi.org/10.3389/fonc.2022.958905

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524149/
https://www.ncbi.nlm.nih.gov/pubmed/36185252
http://dx.doi.org/10.3389/fonc.2022.958905

Ejemplares similares